Full Prescribing Info
Dosage/Direction for Use

Allergic conditions
Adult: Initially, 4 mg tid, adjusted as necessary. Usual: 12-16 mg daily in 3-4 divided doses. Max: 32 mg/day.
Child: 2-6 yr
2 mg bid or tid. Max: 12 mg daily; 7-14 yr 4 mg bid or tid. Max: 16 mg daily.
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Narrow-angle glaucoma, bladder neck obstruction, pyloroduodenal obstruction, symptomatic prostatic hyperplasia, stenosing peptic ulcer. Concurrent use w/ MAOIs. Debilitated elderly, newborn or premature infants. Lactation.
Special Precautions
Patient w/ CV disease including HTN and ischaemic heart disease, increased intraocular pressure, asthma or other chronic breathing disorders, thyroid dysfunction. Pregnancy. Patient Counselling May impair ability to perform activities requiring mental alertness and motor coordination (e.g. operating machinery or driving).
Adverse Reactions
Confusion, disturbed coordination, dizziness, excitation, euphoria, hallucinations, headache, hysteria, insomnia, irritability, nervousness, restlessness, sedation, seizure, sleepiness, tremor, vertigo, hypotension, palpitation, tachycardia, abdominal pain, anorexia, increased appetite, constipation, diarrhoea, nausea, vomiting, xerostomia, difficult urination, urinary retention, urinary frequency, blurred vision, diplopia, tinnitus, acute labyrinthitis, nasal congestion, pharyngitis, thickening bronchial secretion, paraesthesia, hepatitis, cholestasis, hepatic failure, jaundice, angioedema, photosensitivity, rash, urticaria, fatigue, chills, diaphoresis.
Symptoms: CNS depression to stimulation, atropine-like (e.g. dry mouth, fixed, dilated pupils, flushing) and GI symptoms. Management: Induce vomiting w/ syrup of ipecac. If unable to vomit, perform gastric lavage followed by activated charcoal. Saline cathartics may be useful for quick dilution of bowel content by osmosis. Vasopressors may be used for hypotension.
Drug Interactions
May have additive effects w/ CNS depressants e.g. hypnotics, sedatives, tranquilizers, antianxiety agents.
Potentially Fatal: MAOIs prolong and intensify the anticholinergic effects of antihistamines.
Food Interaction
Additive CNS depressant effect w/ alcohol.
Lab Interference
May cause false-positive test result for TCAs in urine or serum.
Cyproheptadine is a sedating antihistamine w/ antimuscarinic, serotonin antagonist and Ca channel blocking properties. It competes w/ histamine for H1-receptor sites on effector cells in the GI tract, blood vessels and resp tract.
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 6-9 hr.
Metabolism: Almost completely metabolised principally to the quaternary ammonium glucuronide conjugate. Undergoes aromatic ring hydroxylation, N-demethylation and heterocyclic ring oxidation.
Excretion: Via urine as conjugates (approx 40%) and faeces (2-20%). Elimination half-life: Approx 16 hr (metabolites).
Oral: Store between 15-30°C.
ATC Classification
R06AX02 - cyproheptadine ; Belongs to the class of other antihistamines for systemic use.
Disclaimer: This information is independently developed by CIMS based on cyproheptadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in